Our studies show DMXAA-522 is more effective than individual agonists in activating the expression of pro-inflammatory cytokines and co-stimulatory molecules, resulting in greater CD8+ T cell priming and anti-tumor activity. This evidence concerns the gene CD8A and neoplasm.